Prot #MK-3475-062-00: A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil versus Placebo+Cisplatin+5-Fluorouracil as First-Line Tre

Project: Research project

StatusActive
Effective start/end date11/18/1511/18/21

Funding

  • Merck Sharp & Dohme Corp. (Prot #MK-3475-062-0002)